Virica Biotech
Virica Biotech is an Ottawa-based biotechnology company developing Viral Sensitizer (VSE™) small molecules that boost viral vector yields by suppressing host cell defenses. It serves cell and gene therapy manufacturers, CDMOs, and vaccine producers through direct enterprise sales and e-commerce.
- Company typePrivate
- Founded2018
- HeadquartersOttawa, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Virica Biotech does
Virica Biotech is an Ottawa-based biotechnology company founded in 2018 that develops proprietary Viral Sensitizer (VSE™) small molecule cell enhancers designed to temporarily suppress innate host cell antiviral defenses during viral vector production. By modulating these cellular responses, VSEs enable viruses to infect, transduce, and replicate more efficiently, addressing a fundamental bottleneck in viral vector manufacturing for cell and gene therapies. The company serves biotech and biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and vaccine producers across AAV, lentiviral, and vaccine production workflows, with reported yield improvements of 2-5x in standard AAV processes and up to 7x in broader applications, alongside projected 46-63% reductions in cost of goods per dose.
The company's product portfolio is built around four integrated assets: (1) the VSE™ small-molecule library, derived from screening more than 15,000 molecules; (2) CellVantage™ AAV, the first off-the-shelf catalog product launched in December 2025; (3) the High Throughput Virology (HTV™) screening platform that has evaluated VSE combinations across over 50 applications and cell-line/virus combinations; and (4) Viric.AI™, an active learning platform co-developed with the University of Ottawa that combines machine learning with iterative experimental feedback to optimize biomanufacturing conditions. The company operates a hybrid go-to-market model combining direct enterprise sales — led by a CCO (Beth Thompson-Webb, ex-Aldevron/Cytiva) and Head of Global Sales (Azra Benson, ex-Thermo Fisher/Danaher/Catalent) — for custom VSE formulations and collaborative development, alongside a self-service e-commerce storefront for standardized products. Revenue is generated through product sales (including the CellVantage™ AAV line), fee-for-service HTV screening, custom formulation development, and a meaningful layer of non-dilutive research funding from NRC IRAP, BioCanRx, FedDev Ontario, NIIMBL, and the Ontario Together Fund, with combined disclosed funding exceeding $5M since founding.
Virica Biotech firmographics
Firmographics- Name
- Virica Biotech
- Legal name
- Virica Biotech Inc.
- Website
- https://viricabiotech.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Virica Biotech is an Ottawa-based biotechnology company developing Viral Sensitizer (VSE™) small molecules that boost viral vector yields by suppressing host cell defenses. It serves cell and gene therapy manufacturers, CDMOs, and vaccine producers through direct enterprise sales and e-commerce.
- Ownership category
- akta.pro rank
Virica Biotech industry classification
Industry- Product category
- Biopharmaceutical Manufacturing Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Viral Clearance, Sterile Filtration & Bioburden Control Technologies (HLAAAJAL)
Keywords
Where Virica Biotech is headquartered
LocationHeadquarters
- HQ city
- Ottawa
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Virica Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- VSE Product Sales: Virica sells its proprietary Viral Sensitizer (VSE™) compounds as products to biotech companies, CDMOs, and gene therapy manufacturers. Products include CellVantage™ AAV and VSE starter kits. Revenue is generated through product sales with direct purchasing available via e-commerce.
- Custom VSE Formulation Development: The company develops customized VSE formulations for specific client applications and manufacturing processes. This includes application-specific VSE combinations optimized for particular cell lines and viral vectors.
- Research Grants and Collaborations: Virica receives funding through collaborative research projects with government agencies and industry partners, including BioCanRx grants, NIIMBL project funding, and NRC IRAP support.
- High-Throughput Virology Services: Fee-for-service screening and optimization services using the HTV platform to identify optimal VSE combinations for client-specific applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | CellVantage AAV Product |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Virica Biotech product offering
Product offeringCore offering
Virica Biotech develops and sells proprietary small molecule cell enhancers called Viral Sensitizers (VSE™) that temporarily reduce host cell antiviral defenses during viral vector and vaccine manufacturing, enabling higher yields, improved quality, and lower production costs. The company sells off-the-shelf VSE products (such as CellVantage™ AAV), provides custom formulation development, and operates the High Throughput Virology (HTV™) screening platform along with the Viric.AI™ active learning platform to optimize biomanufacturing processes for cell and gene therapy and vaccine producers.
Product overview
Virica Biotech is a cell enhancer company offering a platform technology centered on Viral Sensitizers (VSE™) - proprietary small molecule cell enhancers that temporarily reduce host cell defenses during production to boost viral vector and vaccine manufacturing yields. The core VSE™ Technology Platform serves as the foundation, from which specific application products like CellVantage™ AAV (an off-the-shelf additive for AAV production workflows) and CellVantage™ AAV Starter Kit are derived. The company also offers Viric.AI™, an active learning platform using machine learning for biomanufacturing optimization, and the HTV™ (High Throughput Virology) platform for screening and formulation development. VSEs are applicable across cell and gene therapies, lentiviral vector production, and vaccine manufacturing.
Differentiator
Problem solved
Functional benefit
Brands
- Viral Sensitizers (VSE™): Proprietary small molecule cell enhancers that temporarily reduce host cell defenses during production, allowing viruses to infect, transduce, and replicate better, resulting in higher yields, quality, and scale-up success.
- CellVantage™ AAV
- Viric.AI™
- HTV™ (High Throughput Virology)
Products and services
- VSE™ (Viral Sensitizers) Technology Platform Proprietary library of small molecule cell enhancers called Viral Sensitizers that temporarily reduce host cell antiviral defenses during production, allowing viruses to infect, transduce, and replicate better. Results in higher yields (up to 7x), improved quality attributes, and better scale-up success for viral vector and vaccine manufacturing. Sold to biotech companies, CDMOs, and gene therapy manufacturers.
- CellVantage™ AAV Off-the-shelf VSE enhancer product designed to drop into existing AAV (adeno-associated virus) production workflows to increase upstream yield. Developed from screening over 15,000 molecules, delivering 2-5x increase in genomic and functional AAV titers across multiple suspension HEK293-based platforms. Targeted at gene therapy manufacturers.
- CellVantage™ AAV Starter Kit Smaller package offering for customers to evaluate CellVantage™ AAV before full-scale adoption. Allows prospective buyers to test the product's performance in their own workflows prior to committing to larger volumes.
- Viric.AI™ Proprietary active learning platform that combines machine learning with iterative experimental feedback to guide experimental design, identify high-value conditions earlier, reduce development timelines, and improve yield optimization in biomanufacturing. Targeted at biomanufacturers developing gene therapies and vaccines.
- HTV™ (High Throughput Virology) Platform Proprietary high-throughput screening platform ensuring purpose-built and optimal VSE combinations for current and emergent viral vector and vaccine manufacturing applications. Evaluated across 50+ cell line and virus combinations. Used for fee-for-service screening and optimization engagements with clients.
- Custom VSE Formulation Development Professional service in which Virica develops customized VSE formulations optimized for specific client applications, cell lines, and viral vector manufacturing processes. Targeted at biotech and gene therapy manufacturers requiring tailored optimization.
- High-Throughput Virology Screening Services Fee-for-service screening and optimization services using the HTV platform to identify optimal VSE combinations for client-specific applications in viral vector production. Targeted at CDMOs, biotech companies, and academic manufacturing centers.
Quantifiable outcome
- Up to 7x yield increase in viral vector production
- +6 more outcomes
Companies that use Virica Biotech
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Virica Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
Virica Biotech partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and important.
- NIIMBLcoreNIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals) public-private partnership funding 39 awards to support domestic biopharmaceutical production. Virica participates in MIT-led consortium with EMD Millipore and Landmark Bio to reduce empty viral capsids in AAV production.
- University of Ottawa (Dr. Francesco Gentile's lab)importantCollaboration developing Viric.AI active learning platform. Combines machine learning with iterative experimental feedback for biomanufacturing optimization. Platform being deployed through Canada's Pandemic Preparedness Hub (CP2H).
- FUJIFILM BiosciencescoreCollaboration under the NRC IRAP Canada-Japan Corporate Co-Innovation Program to optimize Virica's VSE formulation for FUJIFILM Biosciences' BalanCD HEK293 media. Project aims to create an off-the-shelf enhancer-media combination for gene therapy manufacturers, combining Virica's HTV platform with FUJIFILM's media expertise and scale-up capabilities to improve AAV productivity.
- Ottawa Hospital Research Institutecore$1 million collaborative project with Dr. Jean-Simon Diallo's lab selected for BioCanRx grant financing. Project generates regulatory assays and procedures to advance VSE technology for lentiviral production used by academic institutes and large-scale producers including BMC.
- eXmoor pharmacoreCollaboration funded by Canada-UK government initiative to develop VSE formulations for AAV production at scale. Project leverages Virica's VSE technology and eXmoor's process development expertise to reduce gene therapy manufacturing costs. Expected to complete in 2025.
- Ginkgo BioworkscoreStrategic partnership to improve AAV gene therapy manufacturing. Virica provides its VSE panel for high-throughput AAV production screening while Ginkgo utilizes its advanced screening platform to test VSEs directly in clients' cell lines. Aims to reduce high AAV manufacturing costs.
- NIIMBL (with AstraZeneca and Sartorius Stedim Biotech)coreVirica leads NIIMBL project to enhance CAR-T manufacturing using small-molecule enhancers. Project aims to increase lentiviral vector production outputs, cut costs, and improve manufacturing efficiency. Supported by NIIMBL members AstraZeneca and Sartorius Stedim Biotech.
- Carleton UniversitycoreMulti-year, multi-million-dollar research and infrastructure partnership. Virica's new facility at Carleton University expands bioprocessing services and enables talent development with experiential learning opportunities for students. Partnership drives innovation in advanced therapy manufacturing.
- National Research Council of Canada (NRC)coreOngoing collaboration providing advisory services and funding through NRC IRAP. Supports Canada-Japan Co-Innovation Program projects and other international collaboration initiatives.
- CytivaimportantCollaboration on AAV production optimization in ELEVECTA transient cell line. Joint development of VSE formulations validated at 10L scale demonstrating 2-4 fold titer improvements and 63% cost reduction potential.
- Culture BiosciencesimportantCollaboration using cloud-connected 250mL bioreactors with Virica's VSE enhancers and DoE optimization. Achieved 2-5 fold AAV titer improvements. Enables rapid screening and scalable process optimization.
Scale indicators7 records
Recent moves8 records
Expansion highlights7 records
Virica Biotech competitors and assessment
Company assessmentDirect peers
- ReiThera: ReiThera is a biotech developing vaccines and gene therapies using its proprietary ReiCell-AAV cell line. Its partnership with Virica integrated VSEs into ReiThera's AAV platform, achieving 3-4 fold productivity improvements in a directly comparable application.
- FUJIFILM Biosciences: FUJIFILM Biosciences provides cell culture media (including BalanCD HEK293) and process development services for biomanufacturing. Its Canada-Japan co-innovation partnership with Virica is creating an off-the-shelf enhancer-media combination for gene therapy manufacturers.
- Aldevron: Aldevron (acquired by Danaher) manufactured plasmid DNA, mRNA, and proteins for gene therapy and vaccine developers. It serves an overlapping customer base to Virica; Virica's current CCO previously led commercial at Aldevron.
- Ginkgo Bioworks: Ginkgo Bioworks provides cell programming and biomanufacturing services, including high-throughput AAV production screening. Its strategic partnership with Virica integrates VSEs into Ginkgo's screening services for gene therapy clients.
- Cytiva: Cytiva (a Danaher company) provides media, bioreactors, and process development services for cell and gene therapy manufacturing. It is both a Virica partner (ELEVECTA cell line co-development) and a competing supplier of upstream bioprocess solutions.
- Culture Biosciences: Culture Biosciences operates cloud-connected bioreactors for bioprocess development and optimization. It partners with Virica to combine its 250mL bioreactor platform with VSE enhancers and DoE optimization for AAV clients.
- eXmoor Pharma: eXmoor Pharma is a CDMO specializing in cell and gene therapy process development and manufacturing. Its UK-Canada partnership with Virica combines VSE formulations with eXmoor's AAV process development expertise to deliver scaled yield improvements.
Broad incumbents
- Lonza: Lonza is a global CDMO with significant cell and gene therapy manufacturing capacity, offering media, process development, and viral vector production services that compete broadly with Virica's served market.
- Thermo Fisher Scientific: Thermo Fisher's life sciences tools and bioproduction businesses serve cell and gene therapy manufacturers with media, reagents, and process services. As a large incumbent it competes indirectly in upstream yield optimization and has historically employed Virica's commercial leadership.
- Sartorius Stedim Biotech: Sartorius offers bioprocessing equipment, consumables, and reagents for viral vector and vaccine manufacturing. It is also a NIIMBL project partner supporting Virica's CAR-T work, but its broader bioprocess portfolio creates competitive overlap in upstream yield optimization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Virica Biotech social profiles
Digital presenceVirica Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Virica Biotech leadership team
Management profileNumber of profiles
Profiles10 records
Virica Biotech funding detail
Funding detailFunding overview
Funding rounds8 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Virica Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Virica Biotech
What does Virica Biotech do?
Virica Biotech develops and sells proprietary small molecule cell enhancers called Viral Sensitizers (VSE™) that temporarily reduce host cell antiviral defenses during viral vector and vaccine manufacturing, enabling higher yields, improved quality, and lower production costs. The company sells off-the-shelf VSE products (such as CellVantage™ AAV), provides custom formulation development, and operates the High Throughput Virology (HTV™) screening platform along with the Viric.AI™ active learning platform to optimize biomanufacturing processes for cell and gene therapy and vaccine producers.
Is Virica Biotech a public or private company?
Virica Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Virica Biotech founded?
Virica Biotech was founded in 2018. It employs 11 to 50 people.
Where is Virica Biotech based?
Virica Biotech is headquartered in Ottawa, Canada, in the North America region.
How does Virica Biotech make money?
Four revenue lines are on record. VSE Product Sales are the primary driver. The others are custom VSE Formulation Development, research Grants and Collaborations and high-Throughput Virology Services.
Who are Virica Biotech's main competitors?
Direct peers on record are ReiThera, FUJIFILM Biosciences, Aldevron, Ginkgo Bioworks, Cytiva, Culture Biosciences and eXmoor Pharma. Broad incumbents are Lonza, Thermo Fisher Scientific and Sartorius Stedim Biotech.
Does Virica Biotech have an API?
No public API is recorded for Virica Biotech.
What industry is Virica Biotech in?
Virica Biotech's product category is Biopharmaceutical Manufacturing Reagents. Its primary akta.pro industry code is HLAAAKAD, Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.